Top results for Vetter in the University of St. Gallen benchmarking | News

RAVENSBURG, Germany–(BUSINESS WIRE)–April 7, 2022–

Vetter, one of the world’s leading contract development and manufacturing organizations (CDMOs), has successfully participated in laboratory benchmarking with its receiving laboratory over the past year. the University of St. Gallen (HSG) participated in the project as a scientific partner. This educational institution not only offers a wealth of comparative data, but also knows the requirements of the authorities, for example the FDA (US Food and Drug Administration). This independent review supports Vetter’s operational excellence strategy.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220407005776/en/

© Vetter Pharma International GmbH: Thanks to sustainably robust processes, Vetter presents itself as a stable and long-lasting partner for customers all over the world.

“Comparing ourselves to other companies in the industry is a great way for Vetter to examine our own performance and derive valuable connection points for our laboratory divisions,” explained

Dr. Anne Kuhlmann, Vice President of Quality Control. Using a standardized questionnaire, key figures on quality, cost level and productivity were recorded. HSG evaluated the data and then compared it with other companies in the industry.

Recently, the benchmarking results were released: in terms of overall performance, Vetter is among the top ten percent performers in the industry. “The balanced performance result in the areas of effectiveness and efficiency is particularly noteworthy,” said Gian-Andri Steiger, Research Associate at HSG. If the results in these two areas are in harmony, this indicates sustainably robust processes within the framework of scientific benchmarking – while delivering consistently high quality. “Vetter thus proves to be a stable and long-lasting partner for its customers,” said Steiger.

After the microbiology and chemical analysis departments had already taken part – also with very good marks – the audit of the goods receipt laboratory was the company’s third benchmarking with the University of St. Gallen. “The collaboration with HSG has been very strong and profitable,” said Dr. Kuhlmann. Another important result for Vetter is the expansion of the network of all benchmarking participants, including customers and competitors who participate in a monthly roundtable. This enables a quick and easy exchange on a variety of complex topics that affect the industry and enables continuous progress to be made together for the benefit of patients around the world.

Find Vetter’s press kit and more background information here:

About the University of St. Gallen (HSG)

For over a hundred years, the HSG is part of St. Gallen – at first as a “business academy”, today as a university. In line with HSG’s vision and guiding principles, it is internationally recognized not only for its teaching but also for its research in selected fields. The HSG conducts problem-oriented fundamental research on the one hand and research-based teaching on the other. In doing so, it systematically exploits synergies with traditionally practice-oriented research. As a respected research institution, it offers attractive research conditions for young and experienced scientists, with targeted support for young researchers.

About Vetter

Based in Ravensburg, Germany, Vetter is a world-leading, family-owned contract development and manufacturing organization (CDMO) with production sites in Germany, Austria and the United States. Currently employing more than 5,700 people worldwide, the company has a long history of supporting biotech and pharmaceutical customers large and small. Vetter services ranging from early stage development support, including clinical manufacturingfor commercial supply and many packaging solutions for vials, syringes and cartridges. As a leading solutions provider, Vetter values ​​its responsibility to meet the needs of its customers by developing devices that help increase patient safety, convenience and improve compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220407005776/en/

CONTACT: Vetter Pharma International GmbH

Markus Kirchner

Corporate Spokesperson / Media Relations

Eywiesenstraße 5

88212 Ravensburg

Germany

Telephone: +49 (0)751-3700-3729

Email: [email protected]

KEYWORD: GERMANY EUROPE

KEYWORD INDUSTRY: PACKAGING MANUFACTURING BIOTECHNOLOGY HEALTH UNIVERSITY PHARMACEUTICAL OTHER SCIENCE SCIENCE EDUCATION

SOURCE: Vetter

Copyright BusinessWire 2022.

PUBLISHED: 04/07/2022 11:27 AM/DISC: 04/07/2022 11:27 AM

http://www.businesswire.com/news/home/20220407005776/en

Copyright BusinessWire 2022.

Comments are closed.